Mobic

[Guest guest]

Here's what I found on Mobic: - Rogene

FACTS ABOUT MOBIC® (MELOXICAM)

GENERIC NAME

Meloxicam

PRODUCT DESCRIPTION

Mobic® (meloxicam) is a nonsteroidal anti-inflammatory

drug (NSAID). MOBIC is available in 7.5 mg and 15 mg

once-daily tablets.

INDICATION

MOBIC is indicated for relief of the signs and

symptoms of osteoarthritis (OA) and rheumatoid

arthritis (RA).1 The U.S. Food and Drug Administration

approved MOBIC tablets in OA on April 14, 2000 and in

RA on July 16, 2004.

DOSING AND ADMINISTRATION

The lowest dose of MOBIC should be sought for each

patient. For the treatment of both osteoarthritis and

rheumatoid arthritis, the recommended starting and

maintenance oral dose of MOBIC is 7.5 mg once daily.

Some patients may receive additional benefit by

increasing the dose to 15 mg once daily. The maximum

recommended daily dose of MOBIC is 15 mg, regardless

of formulation. Doses higher than 15 mg per day should

not be taken due to increased risk of serious stomach

and intestinal problems. MOBIC may be given without

regard to timing of meals.1

CLINICAL TRIALS

The use of MOBIC for the treatment of the signs and

symptoms of osteoarthritis was evaluated in the United

Stats through a double-blind, controlled trial

involving 464 patients treated with MOBIC for 12

weeks. MOBIC was shown to be effective in the

treatment of osteoarthritis and demonstrated

gastrointestinal tolerability similar to placebo.2

Outside the United States, the use of MOBIC for the

management of signs and symptoms of osteoarthritis was

evaluated in six double-blind, active-controlled

trials in which a total of 9,589 patients were treated

for four weeks to six months. In these trials, the

efficacy of MOBIC, in doses of 7.5 and 15 mg/day, was

comparable to 20 mg piroxicam and 100 mg diclofenac SR

(slow release) and was consistent with the efficacy

see in the U.S. trial.1

The use of MOBIC for the treatment of the signs and

symptoms of rheumatoid arthritis was evaluated in a

double-blind, controlled multinational trial involving

1184 patients treated with MOBIC for 12 weeks. MOBIC

(7.5 mg, 15 mg and 22.5 mg daily) was compared to

placebo.

The primary endpoint in this study was the ACR20

response rate, a composite measure of clinical,

laboratory and functional measures of RA response.

Patients receiving Mobic® (meloxicam) tablets 7.5 mg

and 15 mg daily showed significant improvement in the

primary endpoint compared with placebo. No incremental

benefit was observed with the 22.5 mg dose compared to

the 15 mg dose.1 Higher doses of MOBIC (22.5 mg and

greater) have been associated with an increased risk

of serious GI events; therefore the daily dose of

MOBIC should not exceed 15 mg.1

MOBIC was developed by Boehringer Ingelheim.

1 MOBIC Package Insert.

2 Yocum, D., et al. Efficacy and Safety of Meloxicam

in the Treatment of Osteoarthritis; Results of a Phase

III Double-Blind, Placebo-Controlled Trial. Presented

at American College of Rheumatology Annual Meeting,

November 14, 1999.

About MOBIC® (meloxicam) tablets

MOBIC is a nonsteroidal anti-inflammatory drug (NSAID)

indicated to help relieve the signs and symptoms of

osteoarthritis and rheumatoid arthritis. MOBIC is

available in 7.5 mg and 15 mg once-daily tablets.

Doses higher than 15 mg per day should not be taken

due to increased risk of serious stomach and

intestinal problems.

You should not take MOBIC if you have had an

allergic-type reaction to meloxicam, aspirin or other

NSAIDs. MOBIC should not be taken if you have asthma.

MOBIC cannot be taken in the place of aspirin and is

not intended to help prevent a heart attack or stroke.

Pregnant women should consult with their physicians

before taking MOBIC, however, MOBIC should not be

taken by women in late pregnancy. Tell your doctor if

you have advanced kidney disease or any symptoms

suggesting liver problems. Rarely, bleeding or other

serious stomach problems can occur without warning.

In clinical trials, the most common side effects were

diarrhea, indigestion, headache, and flu-like

symptoms. Tell your doctor if you experience any

unusual symptoms.

Mobic® (meloxicam) was developed by Boehringer

Ingelheim. For more information, see full Prescribing

Information.

--- Liz <elizabethhogg@...> wrote:

> hi everyone,

>

> i just finished my semester of school and did very

> well. i have

> something to throw at you guys. i went and saw a

> rheu someone that i

> have been seeing until i can get in with this other

> one in june, he is

> supposed to be the best. i have felt really good all

> week no pain and

> no flare ups until yesterday. she started me on

> mobic and i didnt seem

> to have any pain at all on it. so what could it be?

> fibro or not? i

> dont where else to look. i had my explant the 2nd

> week in april, and i

> am wondering if i am still dealing with that

> problem. anyone got any

> ideas? has anyone else tried mobic? i know it is

> supposed to be bad

> for you but if felt really well on it. got any

> suggestions?

>

> liz

>

>

>